Refine
Document Type
- Part of Periodical (2)
- Article (1)
Language
- English (3)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- 17-AAG (1)
- Anthocerotophyta (1)
- HSP90 inhibitors (1)
- Marchantiophyta (1)
- gallbladder cancer (1)
- gallbladder cancer xenografts (1)
- geldanamycin (1)
Institute
A catalogue of 107 species of liverworts (Marchantiophyta) and 8 species of hornworts (Anthocerotophyta), recorded from Assam, India is presented. This includes three new records for India viz., Cololejeunea denticulata (Horik.) S. Hatt., C. inflata Steph., Plagiochila furcifolia Mitt., and three species viz., Cololejeunea desciscens Steph. Colura ari (Steph.) Steph., Lopholejeunea eulopha (Taylor) Schiffn. new to mainland. Twelve species are new record for Eastern Himalayan bryo-geographical territory, 20 species as new to Assam and seven species are endemic to Indian regions.
A preliminary study has been made for Borail Wild Life Sanctuary, Assam, India. A total of 25 species of liverwort (Marchantiophyta) and one species of hornwort (Anthocerotophyta) have been enumerated. Of these, Frullania berthoumieuii is new to India, Caudalejeunea reniloba new to North East India, 13 species new to Assam and 11 species are reported for the first time from Borail WLS. Folioceros paliformis is rediscovered after its type.
Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NOD-SCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors.
In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies.
In vivo, 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6% reduction in tumor size in the treatment group compared to control mice (p < 0.05).
The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87%) and it was strongly expressed in 70 cases (33%), moderately in 58 cases (28%), and weakly in 54 cases (26%).
Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development.